Patent EP0244677A2 successfully refreshed from Google Patents.
EP0244677A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method of producing peptides, recombinant plasmid for use in the same and myeloma cells transformed with the same
Assignee: Daiichi Pharmaceutical Co Ltd
•
Filing: 1987-04-14
•
Granted: —
•
Expires: 2007-04-14
Abstract
Abstract A method of producing desired peptides by transforming mammalian cells and cultivating the transformed cells can be improved by using myeloma cells as the mammalian cells and/or using a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of the gene coding for the desired peptide.
Inventors
- 👤 Kenji Daiichi Seiyaku Research Inst. Murakami
- 👤 Yasuaki Daiichi Seiyaku Research Inst. Tonooka
- 👤 Norie Daiichi Research Inst. Saito
- 👤 Kokichi Daiichi Seiyaku Research Inst. Nakasuji
- 👤 Norifumi Daiichi Seiyaku Research Inst. Sugiyama
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 19:42
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; C12N15/63; C12N15/79; C12N15/85; C12N5/00; C12N5/10; C12N2800/00; C12N2800/10; C12N2800/108
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
48 words
A method of producing desired peptides comprising: (l) transforming mammalian cells with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of the gene coding for the desired peptide, (2) cultivating the transformed cells, and (3) purifying the desired peptides.
Claim 2
Independent Claim
48 words
A method of producing desired peptides comprising: (l) transforming mammalian cells with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of the gene coding for the desired peptide, (2) cultivating the transformed cells, and (3) purifying the desired peptides.
Claim 3
Independent Claim
48 words
A method of producing desired peptides comprising: (l) transforming myeloma cells with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of the gene coding for the desired peptide; (2) cultivating the transformed cells, and (3) purifying the desired peptides.
Claim 4
Independent Claim
48 words
A method of producing desired peptides comprising: (l) transforming myeloma cells with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of the gene coding for the desired peptide; (2) cultivating the transformed cells, and (3) purifying the desired peptides.
Claim 5
Dependent Claim
25 words
A vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of a gene coding for a desired peptide.
Claim 6
Dependent Claim
25 words
A vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of a gene coding for a desired peptide.
Claim 7
Dependent Claim
30 words
A mammalian cell transformed with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of a gene coding for a desired peptide.
Claim 8
Dependent Claim
30 words
A mammalian cell transformed with a vector having the SV40 early promoter sequence on both the 5ʹ upstream and 3ʹ downstream sides of a gene coding for a desired peptide.
Claim 9
Dependent Claim
16 words
A mammalian cell as claimed in claim 4, wherein said mammalian cell is a myeloma cell.
Claim 10
Dependent Claim
28 words
The method as claimed in claim 2, wherein said myeloma cell is selected from the group consisting of mouse myeloma cells, rat myeloma cells and human myeloma cells.
Claim 11
Dependent Claim
26 words
The method as claimed in claim 6, wherein said mouse myeloma cells are selected from the group consisting of P3-X63-Ag8-Ul HGPRT⁻, X63-Ag8-6.5.3 HGPRT⁻ and SP2/0-Agl4 HGPRT⁻.
Claim 12
Independent Claim
29 words
The method as claimed in claims 1 or 2, wherein said desired peptide is selected from the group consisting of lymphokines, hormones, antigenic proteins, tissue plasminogen activator and somatomedins.
Claim 13
Dependent Claim
27 words
The vector as claimed in claim 3, wherein said desired peptide is selected from the group consisting of lymphokines, hormones, antigenic proteins, tissue plasminogen activator and somatomedins.
Claim 14
Dependent Claim
28 words
The mammalian cell as claimed in claim 4, wherein said desired peptide is selected from the group consisting of lymphokines, hormones, antigenic proteins, tissue plasminogen activator and somatomedins.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.